VOLITIONRX LTD — Director's Dealing 2026

Jan 23, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2026-01-22-05:00

Reporting Person: Reynolds Cameron John (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-22-05:00	Common Stock	A	74700	—	Acquired	2629547	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1007718	Indirect
Common Stock	34076	Indirect

Footnotes

F1: On March 17, 2025, the reporting person was awarded 249,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 74,700 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 24,900 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 174,300 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.

F2: The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.